DRUG

+ Watchlist + Portfolio

Bright Minds Biosciences Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $84.74
52-Week Range: $38.00 – $123.75
Market Cap: $770.84M
P/E (TTM): —
EPS (TTM): -2.04
Dividend Yield: —

Advanced Metrics

Price/Book: 3.48
PEG Ratio: —
Return on Equity: -13.63%
Return on Assets: -13.50%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 121.97
Debt/Equity: 0.00
Total Debt: $65.59K
Free Cash Flow: $-18.77M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $528.12M

DRUG Income statement, annual periods, in CAD
CAD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$12.18M	$5.00M	$1.18M	$11.08M
Selling, General & Admin	$2.55M	$2.20M	$1.45M	$2.57M
Operating Expenses	$14.98M	$7.39M	$2.82M	$13.94M
Operating Income	-$14.98M	-$7.39M	-$2.82M	-$13.94M
EBITDA	-$14.97M	-$7.31M	-$2.75M	-$13.86M
Pretax Income	-$14.96M	-$7.37M	-$2.80M	-$12.23M
Net Income	-$14.96M	-$7.37M	-$2.80M	-$12.23M
Diluted EPS	-6.06	-1.98	-0.65	-1.78
Diluted Shares	2.47M	3.72M	4.31M	6.88M

DRUG Balance Sheet statement, annual periods, in CAD
CAD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$11.63M	$6.75M	$5.72M	$82.91M
Receivables	$155.78K	$36.98K	$50.22K	$413.07K
Current Assets	$11.95M	$6.81M	$5.99M	$84.31M
Total Assets	$12.09M	$6.88M	$6.10M	$84.42M
Current Liabilities	$1.47M	$280.86K	$528.68K	$2.34M
Total Debt	$139.91K	$73.55K	$118.96K	$125.78K
Total Liabilities	$1.54M	$280.86K	$568.26K	$2.38M
Retained Earnings	-$24.17M	-$31.55M	-$34.35M	-$46.58M
Shareholders' Equity	$10.54M	$6.60M	$5.54M	$82.04M
Working Capital	$10.48M	$6.53M	$5.46M	$81.97M

DRUG Cash Flow statement, annual periods, in CAD
CAD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.59M	-$7.02M	-$1.85M	-$8.69M
Free Cash Flow	-$13.59M	-$7.02M	-$1.85M	-$8.69M
Depreciation & Amortisation	$6.04K	$72.45K	$73.36K	$76.87K
Stock-Based Compensation	$875.06K	$1.15M	$839.77K	$3.18M
Financing Cash Flow	$5.20M	$2.19M	$810.57K	$85.57M
Net Change in Cash	-$8.39M	-$4.83M	-$1.04M	$76.88M

DRUG Income statement, quarterly periods, in CAD
CAD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.56M	$2.69M	$4.78M	$5.66M	$13.05M
Selling, General & Admin	$676.16K	$591.94K	$756.40K	$1.09M	$2.23M
Operating Expenses	$3.35M	$3.30M	$5.66M	$6.90M	$15.32M
Operating Income	-$3.35M	-$3.30M	-$5.66M	-$6.90M	-$15.32M
EBITDA	-$3.33M	-$3.28M	-$5.65M	-$6.88M	-$15.30M
Pretax Income	-$2.95M	-$5.24M	-$4.09M	-$7.57M	-$10.46M
Net Income	-$2.95M	-$5.24M	-$4.09M	-$7.57M	-$10.46M
Diluted EPS	-0.42	-0.74	—	-0.97	-1.09
Diluted Shares	7.04M	7.08M	—	7.76M	9.59M

DRUG Balance Sheet statement, quarterly periods, in CAD
CAD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$55.68M	$51.39M	$82.91M	$89.05M	$309.69M
Receivables	$233.57K	$272.63K	$413.07K	$502.68K	$1.14M
Current Assets	$56.31M	$52.37M	$84.31M	$90.79M	$312.29M
Total Assets	$56.47M	$52.50M	$84.42M	$90.88M	$312.37M
Current Liabilities	$637.97K	$604.99K	$2.34M	$1.58M	$3.83M
Total Debt	$166.60K	$141.03K	$125.78K	$104.90K	$82.13K
Total Liabilities	$726.81K	$667.83K	$2.38M	$1.60M	$3.83M
Retained Earnings	-$37.25M	-$42.49M	-$46.58M	-$54.14M	-$64.60M
Shareholders' Equity	$55.74M	$51.83M	$82.04M	$89.28M	$308.53M
Working Capital	$55.68M	$51.76M	$81.97M	$89.21M	$308.46M

DRUG Cash Flow statement, quarterly periods, in CAD
CAD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.43M	-$3.50M	-$1.27M	-$5.82M	-$9.25M
Free Cash Flow	-$2.43M	-$3.50M	-$1.27M	-$5.82M	-$9.25M
Depreciation & Amortisation	$22.48K	$15.85K	$17.01K	$19.79K	$19.80K
Stock-Based Compensation	$615.91K	$1.32M	$1.07M	$1.29M	$1.20M
Financing Cash Flow	$225.38K	-$16.87K	$33.32M	$13.39M	$228.47M
Net Change in Cash	-$2.20M	-$3.52M	$32.05M	$7.57M	$219.22M

Market Snapshot

About

Bright Minds Biosciences Inc. is a biotechnology company focused on developing novel drugs targeting neuropsychiatry and pain disorders. The company's drug development platform centers on selective serotonin receptor agonists designed to avoid the hallucinogenic effects of traditional psychedelics. Bright Minds is developing treatments for conditions including epilepsy, pain, depression, and other neurological and psychiatric disorders. The company employs structure-based drug design and medicinal chemistry to create differentiated therapeutic candidates. Bright Minds aims to address significant unmet medical needs in central nervous system disorders.